Recent data presented at the American Society of Clinical Oncology annual meeting detail the efficacy of two experimental therapies, ivonescimab and amivantamab, in treating advanced malignancies.

在美國臨床腫瘤學會（ASCO）年會上發表的最新數據，詳細列出了兩種實驗性療法 ivonescimab 與 amivantamab 治療晚期惡性腫瘤的療效。

The Harmoni-6 Phase 3 trial, conducted exclusively within China, evaluated ivonescimab, a bispecific antibody targeting PD-1 and VEGF. When administered in conjunction with chemotherapy for patients with squamous non-small-cell lung cancer (NSCLC), the agent demonstrated a 34% reduction in mortality risk. Median survival was recorded at 27.9 months, compared to 23.7 months for the control group receiving tislelizumab and chemotherapy. While these results are statistically significant, clinical observers, including Dr. Suresh Ramalingam, have noted that the homogeneity of the trial population may limit the immediate generalizability of the data to global cohorts. Furthermore, the incidence of hemorrhage was higher in the ivonescimab group, although severe cases remained below 3%.

Harmoni-6 第三期臨床試驗專門在中國進行，評估了 ivonescimab 這種針對 PD-1 與 VEGF 的雙特異性抗體。當其與化療併用於鱗狀非小細胞肺癌（NSCLC）患者時，該藥物顯示死亡風險降低了 34%。中位生存期記錄為 27.9 個月，而對照組（接受 tislelizumab 與化療）則為 23.7 個月。雖然這些結果在統計學上具有顯著意義，但包括 Suresh Ramalingam 醫生在內的臨床觀察者指出，試驗人群的同質性可能會限制這些數據立即推廣至全球群體的適用性。此外，ivonescimab 組的出血發生率較高，儘管嚴重病例仍低於 3%。

From a market perspective, the potential for ivonescimab to displace established checkpoint inhibitors, such as Merck's Keytruda, has influenced the valuation of Summit Therapeutics, which holds the licensing rights outside of China. However, industry analysts suggest that the emergence of antibody-drug conjugates may constrain the market penetration of PD-1/VEGF therapies. Concurrent with these findings, data from an 11-nation study on amivantamab, developed by Johnson & Johnson, indicated significant tumor regression in 42% of patients with refractory head and neck cancers. Notably, 15 participants achieved complete tumor eradication. The drug, which utilizes a triple-action mechanism to block growth proteins and activate immune responses, is currently under investigation in approximately 60 additional clinical trials targeting diverse malignancies, including gastric and colorectal cancers.

從市場角度來看，ivonescimab 取代如 Merck 的 Keytruda 等既有檢查點抑制劑的潛力，影響了持有中國以外地區授權的 Summit Therapeutics 的估值。然而，產業分析師認為，抗體藥物接合物（ADC）的出現可能會限制 PD-1/VEGF 療法的市場滲透率。與此同時，一項涉及 11 個國家關於 amivantamab（由強生公司 J&J 開發）的研究數據顯示，42% 的難治性頭頸癌患者出現顯著的腫瘤縮小。值得注意的是，有 15 名參與者實現了腫瘤完全根除。該藥物利用三重作用機制來阻斷生長蛋白並激活免疫反應，目前正於約 60 個針對不同惡性腫瘤（包括胃癌與大腸癌）的其他臨床試驗中進行研究。

Ivonescimab and amivantamab have demonstrated positive clinical signals in specialized patient populations, pending further global validation and expanded trial data.

Ivonescimab 與 amivantamab 在特定患者群體中展現出正面的臨床信號，尚待進一步的全球驗證與擴大試驗數據。